Ad
related to: crispr therapeutics latest news
Search results
Results from the WOW.Com Content Network
CRISPR Therapeutics (NASDAQ: CRSP) is recognized as a pioneer in the field of gene therapy. ... News. Science & Tech. Shopping. Sports. Weather. 24/7 Help. ... On the other hand, the latest ...
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CRISPR Therapeutics wasn’t one of them. The 10 stocks that ...
ZUG, Switzerland and BOSTON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today presented data from the Company’s ongoing Phase 1/2 dose escalation clinical trial evaluating the safety and efficacy of CTX112™, a ...
CRISPR Therapeutics ended the second quarter with $2 billion in cash, equivalents, and marketable securities, higher than the $1.7 billion it had as of the end of 2023.
CRISPR Therapeutics has two next generation approaches with the potential to significantly expand the addressable population with SCD and TDT. The Company continues to advance its internally developed targeted conditioning program, an anti-CD117 (c-Kit) antibody-drug conjugate (ADC), through preclinical studies.
CRISPR Therapeutics has a $3.9 billion market cap at recent prices, but the stock is less expensive than it looks on the surface. With a big cash cushion and a lack of debt, its enterprise value ...
As a result, CRISPR Therapeutics may soon opt to slow down its initiation of new pre-clinical programs, or (perhaps temporarily) shelve programs rather than advancing them into early stage ...
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CRISPR Therapeutics wasn’t one of them. The 10 stocks that ...
Ad
related to: crispr therapeutics latest news